Abstract

Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide and is defined as blood loss greater than 1,000 mL, or blood loss with symptoms of hypovolemia. Primary PPH arises within 24 hours of delivery, while secondary PPH occurs within 12 weeks of delivery. Tranexamic acid (TXA) is an antifibrinolytic that inhibits plasminogen and fibrin binding, thus preventing fibrinolysis and promoting hemostasis. Although uterotonic agents remain the pillar for prevention and treatment of PPH, recent evidence indicates that TXA given prophylactically or as treatment can reduce postpartum blood loss.

Author Details

Katie Waid, BSN and Mary Beth Greenway, DNP, CRNA

Sigma Membership

Non-member

Lead Author Affiliation

Samford University, Birmingham, Alabama, USA

Type

DNP Capstone Project

Format Type

Text-based Document

Study Design/Type

Case Study/Series

Research Approach

Translational Research/Evidence-based Practice

Keywords:

Postpartum Hemorrhage, Blood Loss, Antifibrinolytic, Prevention Measures

Advisor

Greenway, Mary Beth

Degree

Doctoral-Other

Degree Grantor

Samford University

Degree Year

2023

Rights Holder

All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.

All permission requests should be directed accordingly and not to the Sigma Repository.

All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.

Review Type

None: Degree-based Submission

Acquisition

Self-submission

Date of Issue

2023-02-13

Full Text of Presentation

wf_yes

Download

Additional Files

download (84 kB)

download (1616 kB)

Share

COinS